Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›SNY›Vakzimeter FLU

Vakzimeter FLU

Ensayo de Sanofi en Influenza Immunization (del registro, en inglés).

Fase
no aplica
Estado
Completado
Participantes
5.000
previstos
Centros
1
Fin del objetivo primario
feb 2026
fecha real

Título oficial en el registro (en inglés): Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en oct 2024.

De principio a fin

  1. Empieza el ensayo (oct 2024)
  2. Lectura de resultados feb 2026 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Assessing the seasonal influenza vaccination rates among diverse healthy participants 18 years of age through and including 59 years of age (Throughout Study (Approximately 3 months)) (del registro, en inglés)

Qué se prueba

Se busca determinar las tasas de vacunación antigripal en la población alemana durante la temporada respiratoria en curso.

Lo que dice el documentoThe primary objective of this study is to determine the influenza vaccination rates in the German population during the current respiratory season. The study will focus on: 1.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroReal-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage. This study aims to address the gap by assessing current influenza vaccination rates, particularly among those aged 60 and older, to inform public health interventions and encourage healthcare providers to recommend influenza vaccination more proactively. The primary objective of this study is to determine the influenza vaccination rates in the German population during the current respiratory season. The study will focus on: 1. Assessing the vaccination rates among the two main age groups 18 years of age through and including 59 years of age and 60 years of age (inclusive) and older 2. Assessing the vaccination rate among individuals with risk-based vaccination recommendation according to Standing Committee on Vaccination (Ständige Impfkommission) (STIKO) The study will target a disproportionate sample of the German population regarding age: 30% aged 18 years of age through and including 59 year of age and 70% aged 60 years of age (inclusive) and older. Within these age groups, the study targets a representative distribution regarding gender and region. This study is conducted as an online survey that will either be self-completed by the respondents (CAWI) or completed via an interviewer for a subgroup of respondents aged 70+ (CATI). The survey is estimated to last 10 minutes and will comprise of closed-ended questions only (i.e., respondents will not have the possibility to add any free-text). The survey will be conducted in German. The panelists will be divided into strata based on demographic variables like gender and region. Within each stratum, participants will be randomly selected to participate in the survey.

Más ensayos de SNY

EnsayoFaseEstadoLectura de resultados
Avalglucosidase alfa · Mini-COMETFase 2En marcha, sin reclutarsep 2019 (real)
Yellow fever vaccineFase 2En marcha, sin reclutarmay 2022 (real)
Yellow fever vaccine · VYF02Fase 2En marcha, sin reclutarjun 2022 (real)
SAR441344 IVFase 2En marcha, sin reclutarsep 2022 (real)
Meningococcal PolysaccharideFase 3En marcha, sin reclutarmar 2023 (real)
rilzabrutinib · LUMINA 2Fase 2En marcha, sin reclutarmay 2024 (real)

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06800885), actualizada en mar 2026.